Related Experiment Video
Updated: Jun 10, 2025
Imaging In-Stent Restenosis: An Inexpensive, Reliable, and Rapid Preclinical Model
Published on: September 14, 2009
Prediction Model for in-Stent Restenosis Post-PCI Based on Boruta Algorithm and Deep Learning: The Role of Blood
1Cardiovascular Disease Center, Central Hospital of Tujia and Miao Autonomous Prefecture, Hubei University of Medicine, Enshi, Hubei Province, People's Republic of China.
Insights
The cholesterol-to-lymphocyte ratio (CLR) can predict in-stent restenosis (ISR) after percutaneous coronary intervention (PCI). A deep learning model using CLR showed strong predictive performance for ISR, offering new clinical strategies.
Area of Science:
- Cardiology
- Biomarkers
- Artificial Intelligence
Background:
- Percutaneous coronary intervention (PCI) is a primary treatment for acute myocardial infarction (AMI).
- In-stent restenosis (ISR) is a significant limitation following PCI.
- The cholesterol-to-lymphocyte ratio (CLR) is a novel biomarker linked to inflammation and dyslipidemia, potentially predicting ISR.
Purpose of the Study:
- To investigate the predictive value of CLR for ISR.
- To develop and evaluate a deep learning model for ISR prediction using CLR.
Main Methods:
- Retrospective analysis of clinical and laboratory data from 1967 patients.
- Utilized the Boruta algorithm for feature selection.
- Developed a multilayer perceptron (MLP) deep learning model for ISR prediction.
Main Results:
- Patients with ISR had significantly higher CLR and LDL levels.
- The MLP model achieved an AUC of 0.95 on the validation set.
- Key predictors identified included initial stent implants, hemoglobin, Gensini score, CLR, and white blood cell count.
Conclusions:
- CLR demonstrates significant potential as a biomarker for predicting coronary ISR.
- The deep learning-based MLP model shows robust predictive capabilities for ISR.
- Findings offer new insights and strategies for clinical decision-making in PCI management.
Background:
Percutaneous coronary intervention (PCI) is the primary treatment for acute myocardial infarction (AMI). However, in-stent restenosis (ISR) remains a significant limitation to the efficacy of PCI. The cholesterol-to-lymphocyte ratio (CLR), a novel biomarker associated with inflammation and dyslipidemia, may have predictive value for ISR. Deep learning-based models, such as the multilayer perceptron (MLP), can aid in establishing predictive models for ISR using CLR.
Methods:
A retrospective analysis was conducted on clinical and laboratory data from 1967 patients. The Boruta algorithm was employed to identify key features associated with ISR. An MLP model was developed and divided into training and validation sets. Model performance was evaluated using ROC curves and calibration plots.
Results:
Patients in the ISR group exhibited significantly higher levels of CLR and low-density lipoprotein (LDL) compared to the non-ISR group. The Boruta algorithm identified 21 important features for subsequent modeling. The MLP model achieved an AUC of 0.95 on the validation set and 0.63 on the test set, indicating good predictive performance. Calibration plots demonstrated good agreement between predicted and observed outcomes. Feature importance analysis revealed that the number of initial stent implants, hemoglobin levels, Gensini score, CLR, and white blood cell count were significant predictors of ISR. Partial dependence plots (PDP) confirmed CLR as a key predictor for ISR.
Conclusion:
The CLR, as a biomarker that integrates lipid metabolism and inflammation, shows significant potential in predicting coronary ISR. The MLP model, based on deep learning, demonstrated robust predictive capabilities, offering new insights and strategies for clinical decision-making.
More Related Videos
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
04:09Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
Published on: October 10, 2018